Indication
Angioimmunoblastic T-cell Lymphoma
20 clinical trials
33 products
11 drugs
Clinical trial
An Exploratory Clinical Study to Investigate the Effect of autoSTEM-OA and alloSTEM-OA in Participants With Knee Osteoarthritis.Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
FenretinideClinical trial
A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's LymphomaStatus: Recruiting, Estimated PCD: 2025-12-01
Product
ARV-393Product
AUTO4Clinical trial
A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2023-07-01
Clinical trial
Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-cell LymphomaStatus: Recruiting, Estimated PCD: 2028-09-01
Product
AzacytidineClinical trial
Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2026-04-30
Product
WU-CART-007Clinical trial
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin LymphomaStatus: Completed, Estimated PCD: 2019-04-18
Clinical trial
Phase I Study of Carfilzomib for the Treatment of T-Cell LymphomaStatus: Completed, Estimated PCD: 2015-04-01
Product
carfilzomibProduct
BendamustineClinical trial
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II StudyStatus: Active (not recruiting), Estimated PCD: 2020-10-01
Product
Ro-CHOEP-21Clinical trial
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2019-11-01
Drug
cyclophosphamideProduct
DoxorubicinProduct
EtoposideProduct
LenalidomideProduct
PrednisoneProduct
VincristineClinical trial
The Safety and Clinical Efficacy of Human CD7 CAR-T Cell Therapy for Patients With Relapsed/Refractory CD7 Positive T Cell Hematological MaliganaciesStatus: Recruiting, Estimated PCD: 2024-08-01
Product
Anti-CD7 CAR-T cellsClinical trial
A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2016-12-28
Drug
prednisoneDrug
etoposideDrug
VincristineProduct
pralatrexateProduct
Gene expression analysisProduct
Nucleic Acid SequencingProduct
Mutation AnalysisProduct
Microarray analysisProduct
RNA analysisClinical trial
The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological MaliganaciesStatus: , Estimated PCD: 2023-11-26
Product
Anti-TRBC1 CAR-TClinical trial
A Phase Ib/II Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of Relapsed/Refractory Angioimmunoblastic T-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Study of Intratumoral Injection of Ipilimumab in Combination With Local Radiation in Melanoma, Non-Hodkgkin Lymphoma and Colorectal CarcinomaStatus: Terminated, Estimated PCD: 2014-11-01
Product
IpilimumabClinical trial
A Prospective Clinical Study of Chemotherapy Plus Programmed Death-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-cell Lymphoma.Status: Recruiting, Estimated PCD: 2023-04-18
Drug
VarlilumabDrug
GemcitabineProduct
DexamethasoneDrug
CisplatinClinical trial
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-06-30
Drug
R-CHOPDrug
DocetaxelClinical trial
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)Status: Recruiting, Estimated PCD: 2024-06-15
Product
Brentuximab vedotinClinical trial
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2013-12-01
Product
ClofarabineProduct
DuvelisibProduct
Oral azacitidineClinical trial
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCLStatus: Active (not recruiting), Estimated PCD: 2020-08-11
Product
romidepsinDrug
lenalidomideClinical trial
A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients with Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-10-01